BullFrog AI’s Collaboration with Lieber Institute for Brain Development Yields Potentially Groundbreaking Biological Stratification of Brain Expression Data
17 janv. 2024 07h00 HE
|
BullFrog AI Holdings, Inc.
GAITHERSBURG, Md., Jan. 17, 2024 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) (“BullFrog AI” or the “Company”), a technology-enabled drug development company using artificial...
BullFrog AI Announces Issuance of Australian Patent Protecting Novel Prodrugs of Mebendazole and Their Use in Treating Cancer
16 janv. 2024 08h00 HE
|
BullFrog AI Holdings, Inc.
GAITHERSBURG, Md., Jan. 16, 2024 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial...
BullFrog AI to Present at Webull LIVE! Healthcare Webinar on January 17
11 janv. 2024 16h05 HE
|
BullFrog AI Holdings, Inc.
GAITHERSBURG, Md., Jan. 11, 2024 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial...
BullFrog AI Issues Letter to Shareholders
29 déc. 2023 08h00 HE
|
BullFrog AI Holdings, Inc.
GAITHERSBURG, Md., Dec. 29, 2023 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial...
BullFrog AI Launches Preclinical Study to Investigate BF-114’s Potential in Battling Obesity
06 déc. 2023 07h00 HE
|
BullFrog AI Holdings, Inc.
The market for obesity drugs is projected to exceed $77 billion by 2030 Dr. Randy Seeley, a recognized expert on novel treatments for obesity, to lead study GAITHERSBURG, Md., Dec. 06, 2023 ...
BullFrog AI to Present at Benzinga All Access Event on October 20
18 oct. 2023 09h00 HE
|
BullFrog AI Holdings, Inc.
GAITHERSBURG, Md., Oct. 18, 2023 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial...
BullFrog AI Announces Identification of Novel Potential Drug Targets for Colorectal Cancer Using Its AI-Driven bfLEAP™ Platform
05 oct. 2023 08h00 HE
|
BullFrog AI Holdings, Inc.
Discoveries generated by analyzing The Cancer Genome Atlas using proprietary bfLEAP™ platform Target validation will be conducted through partnership with J. Craig Venter Institute (JCVI), a...
BullFrog AI Announces Positive Data from Preclinical Study Evaluating Novel Prodrug of Mebendazole for Treatment of Glioblastoma
26 sept. 2023 08h00 HE
|
BullFrog AI Holdings, Inc.
GAITHERSBURG, Md., Sept. 26, 2023 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using...
BullFrog AI Founder and CEO Vin Singh to Present Company Overview at BioFuture 2023
25 sept. 2023 08h00 HE
|
BullFrog AI Holdings, Inc.
GAITHERSBURG, Md., Sept. 25, 2023 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using...
BullFrog AI Announces Launch of BullFrog Data Networks™, a Data Insights Tool Powered by the bfLEAP™ Platform
20 sept. 2023 08h00 HE
|
BullFrog AI Holdings, Inc.
GAITHERSBURG, Md., Sept. 20, 2023 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ:BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial...